Doctor Discussion Guide
Doctor Discussion Guide
Doctor Discussion Guide Be prepared to talk with a doctor about CPP and your child. Take our Doctor Discussion Guide with you to your pediatrician visit to help you get the answers you need.
Growth Comparison Tool
Growth Comparison Tool
Growth Comparison Tool How does your child compare to other children of the same age? Use our Growth Comparison Tool to track one observable aspect of your child's growth—his or her height.
Register
Register with TooSoon.com today for access to our Growth Comparison Tool and Appointment Reminder.
*Email
*Password
*Re-Type Password
*First Name
*Last Name
*Zip Code
*Has your child been diagnosed with CPP?
Yes
No
*What, if any, medication is your child currently taking for CPP?
Lupron Depot-PED® (leuprolide acetate for depot suspension)
Provera® (medroxyprogesterone)
Synarel® (nafarelin acetate nasal solution)
Other
None
* Required Field
By hitting submit you give TAP Pharmaceutical Products Inc. permission to use the above information to provide you with information on central precocious puberty (CPP) or TAP products. TAP may also use this information to contact you or to send educational materials about other products and services that may interest you. TAP may share information about you with agents and partners acting on our behalf. These agents and partners have agreed that they will not use or disclose information about you except as necessary to perform services on our behalf. TAP will not share information about you with any other third party. This information is intended only for residents of the United States and its territories including Puerto Rico.
Synarel® and Provera® are not trademarks of TAP Pharmaceutical Products Inc.
See below for important safety and other information on Lupron Depot-PED.
All photos are of models and not of users of Lupron Depot-PED or persons suffering symptoms described.
    

Important Safety and Other Information:

Lupron Depot-PED (7.5 mg, 11.25 mg, and 15 mg) is used for the treatment of central precocious puberty. In clinical studies, the most frequent adverse event related to therapy with Lupron Depot-PED was an injection site reaction, seen in 5% of children in the combined studies. The recommended starting dose of Lupron Depot-PED is 0.3 mg/kg/4 weeks (minimum 7.5 mg). Inadequate dosing may result in poor control of the pubertal process.

For further information about Lupron Depot-PED, please see the complete Prescribing Information, as well as the
Patient Product Information.
  
©2005, 2008 Abbott Laboratories, Abbott Park, Illinois, U.S.A.